Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

BPC-157 + TB-500 Blend cycle length: what human studies ran

Not approved — research use onlyCPreclinical research
Short answer: there is no established BPC-157 + TB-500 Blend cycle length, and we found no human studies that report one.

Treatment and follow-up in human studies

No human study durations are recorded.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • BPC-157 + TB-500 Blend combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established BPC-157 + TB-500 Blend cycle length?
No. We found no human studies that report a treatment duration for BPC-157 + TB-500 Blend.
What is the longest human study of BPC-157 + TB-500 Blend?
None is recorded.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
BPC-157 + TB-500 Blend dosing reference Full research page

References

  1. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing Cell Tissue Res. 2019
  2. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review Pharmaceuticals (Basel). 2025
  3. Thymosin beta-4: a multi-functional regenerative peptide. Basic properties and clinical applications Expert Opin Biol Ther. 2012
  4. Peptide Supplements and Their Therapeutic Applications in Sports Medicine Am J Sports Med. 2026
  5. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance Sports Med. 2026
  6. Synthetic Peptides in Pharmacy Compounding: Analysis of PCAC Recommendations and Industry Safety Standards Int J Pharm Compd. 2026
  7. World Anti-Doping Code International Standard: Prohibited List 2026 WADA. 2026
  8. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026) FDA. 2026
  9. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study Jt Dis Relat Surg. 2026
  10. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain Altern Ther Health Med. 2021
  11. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians Am J Sports Med. 2026
  12. Dangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs Mo Med. 2026
  13. Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications JBJS Rev. 2026
  14. Doping control analysis of seven bioactive peptides in horse plasma by liquid chromatography-mass spectrometry Anal Bioanal Chem. 2013